MedTrace Logo

Checkpoint Inhibitors in Patients With Cancer and Underlying Autoimmune Disease

NCT04805099 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 126

Last updated 2021-03-22

No results posted yet for this study

Summary

Patients with cancer and concurrent autoimmune diseases (AID) have been universally excluded from clinical trials evaluating immunotherapy. Data on the safety and efficacy of checkpoint inhibitors in patients with underlying AID is limited. The investigators performed a retrospective multicenter review of medical records of patients with diverse tumor types and underlying AID who received checkpoint inhibitors at Departments of Oncology, affiliated with the Hellenic Cooperative Oncology Group (HeCOG). The primary endpoint was progression-free survival (PFS).

Conditions

Interventions

DRUG

Checkpoint inhibitor

Treatment with checkpoint inhibitors in patients with preexisting autoimmune disease

Sponsors & Collaborators

  • Hellenic Cooperative Oncology Group

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-11-01
Primary Completion
2021-01-30
Completion
2021-02-28

Countries

  • Greece

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04805099 on ClinicalTrials.gov